Osaka, Japan

Tsutomu Yoshikawa

USPTO Granted Patents = 5 


Average Co-Inventor Count = 2.7

ph-index = 3

Forward Citations = 39(Granted Patents)


Location History:

  • Kawachinagano, JP (2000)
  • Osaka, JP (2003 - 2023)

Company Filing History:


Years Active: 2000-2023

Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Tsutomu Yoshikawa: Innovator in Monoclonal Antibody Development

Introduction

Tsutomu Yoshikawa is a prominent inventor based in Osaka, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. With a total of 5 patents, his work has advanced the understanding and treatment of various medical conditions.

Latest Patents

Yoshikawa's latest patents focus on the development of human anti-IL-33 neutralizing monoclonal antibodies. These antibodies exhibit an antagonistic effect against IL-33, a cytokine involved in inflammatory responses. His innovative approach includes the identification of epitopes for multiple anti-IL-33 monoclonal antibodies. He has successfully produced antibodies with high binding ability to IL-33 by introducing mutations in the complementarity-determining regions. This work aims to provide effective therapeutic options for conditions associated with IL-33.

Career Highlights

Throughout his career, Tsutomu Yoshikawa has worked with notable companies such as Minolta Company, Ltd. and Mitsubishi Tanabe Pharma Corporation. His experience in these organizations has contributed to his expertise in the field of biotechnology and patent development.

Collaborations

Yoshikawa has collaborated with esteemed colleagues, including Yasuhiro Fujino and Hiroshi Ochi. These partnerships have fostered innovation and have been instrumental in advancing his research.

Conclusion

Tsutomu Yoshikawa's contributions to the field of monoclonal antibodies highlight his role as a leading inventor in biotechnology. His innovative patents and collaborations continue to influence the development of therapeutic solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…